Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
For local relapse not amenable to reasonable curative surgery or for those with metastatic
chordoma, chemotherapy is recognised as inactive. The major study drug is the small molecular
tyrosine kinase inhibitors targeted at the stem cell factor receptor (KIT) and the
platelet-derived growth factor receptors (PDGFRA and PDGFRB), eg. imatinib. Anlotinib is a
novel tyrosine kinase inhibitor targeting both at VEGFR-2, -3 and PDGFRA and PDGFRB with high
affinity, which also showed broad antitumor activity against EGFR and so on. Thus this
multicenter, two-armed phase II trial of PKUPH-sarcoma 05 intended to investigate the
efficacy and safety of anlotinib versus imatinib on advanced chordoma.
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Collaborators:
3Peking University First Hospital Beijing Cancer Hospital Beijing Jishuitan Hospital Cancer Institute and Hospital, Chinese Academy of Medical Sciences Chinese PLA General Hospital Peking University First Hospital Peking University Shougang Hospital Peking University Third Hospital People's Liberation Army General Hospital (301)